Spots Global Cancer Trial Database for head and neck squamous cell carcinoma (hnscc)
Every month we try and update this database with for head and neck squamous cell carcinoma (hnscc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) | NCT03114280 | Head and Neck S... | TPF2 Radiotherapy wi... | 18 Years - 70 Years | Centre Antoine Lacassagne | |
| Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma | NCT04284540 | Head and Neck S... | Adjuvant hypofr... Definitive Hypo... | 70 Years - | Icahn School of Medicine at Mount Sinai | |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | NCT03735628 | Non-small Cell ... Head and Neck S... Hepatocellular ... | Copanlisib Nivolumab | 18 Years - | Bayer | |
| Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | NCT00911326 | Head and Neck S... | Lymphoseek | 18 Years - | Navidea Biopharmaceuticals | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | NCT06295731 | Head and Neck S... | INBRX-106 Pembrolizumab | 18 Years - | Inhibrx, Inc. | |
| Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | NCT02211027 | Head and Neck S... | Semi-allogenic ... | 18 Years - | University of Pittsburgh | |
| Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT02684253 | Head and Neck S... | Nivolumab Stereotactic Bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | NCT03022409 | Head and Neck S... | Ceralasertib Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer | NCT04001543 | Head and Neck S... | Immunomodulatin... Sip feed contro... | 18 Years - 75 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | NCT03746431 | Advanced Solid ... Endometrial Can... Cervical Cancer Ovarian Cancer Breast Cancer Triple Negative... HER2-negative B... Head and Neck S... Adrenocortical ... Uveal Melanoma | [111In]-FPI-154... [225Ac]-FPI-143... FPI-1175 Infusi... [225Ac]-FPI-143... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) | NCT04220866 | Head and Neck S... | Ulevostinag Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis | NCT00173381 | Oral Cancer Laryngeal Cance... Hypopharyngeal ... | 30 Years - 75 Years | National Taiwan University Hospital | ||
| Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | NCT02764593 | Head and Neck S... | Nivolumab Cisplatin Cetuximab IMRT | 18 Years - | RTOG Foundation, Inc. | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | NCT04849377 | Human Papilloma... Head and Neck S... | RT 50 Gy RT 54 GY RT 60 GY Induction Thera... Carboplatin Cisplatin 200 Cisplatin 240 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | NCT05891171 | Advanced Cancer Advanced Malign... Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Gastroesophagea... Head and Neck S... Non-Small Cell ... Ovarian Cancer Renal Cell Carc... Triple Negative... | AB598 Zimberelimab Carboplatin Pemetrexed Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | NCT04704154 | Solid Tumors | Regorafenib, (S... Nivolumab (Opdi... | 18 Years - | Bayer | |
| A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | NCT05249426 | Head and Neck S... | BI 765063 Ezabenlimab BI 836880 Cetuximab Investigator´s ... | 18 Years - | Boehringer Ingelheim | |
| A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | NCT04069026 | Advanced Solid ... | BAY2416964 BAY2416964 | 18 Years - | Bayer | |
| Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma | NCT04284540 | Head and Neck S... | Adjuvant hypofr... Definitive Hypo... | 70 Years - | Icahn School of Medicine at Mount Sinai | |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | NCT05277051 | Neoplasms | GSK4381562 Dostarlimab GSK4428859A | 18 Years - | GlaxoSmithKline | |
| SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma | NCT03546582 | Head and Neck S... | Pembrolizumab Stereotactic Bo... | 18 Years - | RTOG Foundation, Inc. | |
| The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis | NCT00173381 | Oral Cancer Laryngeal Cance... Hypopharyngeal ... | 30 Years - 75 Years | National Taiwan University Hospital | ||
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies | NCT05473156 | Locally Advance... Non Small Cell ... Head and Neck S... Esophageal Squa... | AP203 AP203 | 18 Years - | AP Biosciences Inc. | |
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | NCT03811652 | Non Small Cell ... Head and Neck S... Small Cell Lung... Pancreatic Duct... Colorectal Canc... Metastatic Cast... | MEDI7247 | 18 Years - 101 Years | MedImmune LLC | |
| Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | NCT04080804 | Head and Neck S... | Nivolumab Relatlimab Ipilimumab | 18 Years - | University of Pittsburgh | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer | NCT03268993 | Head and Neck C... Head and Neck S... Head and Neck C... Head and Neck Tobacco-Related... Carcinoma in Si... Dysplasia Hyperplasia Premalignant Le... | Avmacol | 18 Years - | University of Pittsburgh | |
| Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | NCT04215978 | Advanced Solid ... Non Small Cell ... Head and Neck S... Nasopharyngeal ... | BGB-A445 tislelizumab | 18 Years - | BeiGene | |
| Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer | NCT04001543 | Head and Neck S... | Immunomodulatin... Sip feed contro... | 18 Years - 75 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer | NCT03268993 | Head and Neck C... Head and Neck S... Head and Neck C... Head and Neck Tobacco-Related... Carcinoma in Si... Dysplasia Hyperplasia Premalignant Le... | Avmacol | 18 Years - | University of Pittsburgh | |
| Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma | NCT06102447 | Head and Neck S... | Netopitam Palon... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer | NCT04001543 | Head and Neck S... | Immunomodulatin... Sip feed contro... | 18 Years - 75 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | NCT00911326 | Head and Neck S... | Lymphoseek | 18 Years - | Navidea Biopharmaceuticals | |
| Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | NCT02764593 | Head and Neck S... | Nivolumab Cisplatin Cetuximab IMRT | 18 Years - | RTOG Foundation, Inc. | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | NCT04080804 | Head and Neck S... | Nivolumab Relatlimab Ipilimumab | 18 Years - | University of Pittsburgh | |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | NCT04704154 | Solid Tumors | Regorafenib, (S... Nivolumab (Opdi... | 18 Years - | Bayer | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie | |
| HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma | NCT04369937 | HPV-Related Squ... Head and Neck S... | IMRT (Intensity... Pembrolizumab Cisplatin ISA101b | 18 Years - | University of Pittsburgh | |
| Prognostic Immune Biomarkers in HNSCC | NCT05941676 | Head and Neck C... Squamous Cell C... | Tumour immunopr... | 18 Years - 90 Years | University Hospital Ostrava | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
